MedPath

Palonosetron+Aprepitant+Dexamethasone for highly emetic chemotherapy induced nausea and voimiting

Phase 2
Completed
Conditions
ung cancer
Registration Number
JPRN-UMIN000004865
Lead Sponsor
iigata Lung Cancer Treatment Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
95
Inclusion Criteria

Not provided

Exclusion Criteria

1) Vomiting prior to chemotherapy 2)HEC administration except Day 1. 3)Radiation therapy 4)Contraindication of Dexamethasone 5)Symptomatic brain meta 6)Hypersensitivity for PaIonosetron, Aprepitant, Dexamethasone

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath